Ballicules.com

Paroxetine CR

PAXIL CR

What it isControlled-release serotonin reuptake inhibitor with antimuscarinic activity (PAXIL CR, 1999); depression and PMDD.

Why this oneIts enteric Geomatrix tablet has a gentler GI onset, and the CR label carries PMDD.

What limits itDiscontinuation is especially severe if stopped abruptly. Sexual dysfunction, weight gain, and CYP2D6 inhibition often govern choice.

FDA-approved for

FDA label

BOXED WARNING Increased risk of suicidal thoughts and behaviors in pediatric and young adult patients; monitor closely.
FDA dosingPopulationStartTargetMax
Major depressive disorderadults25 mg QD25 mg QD62.5 mg QD
Panic disorderadults12.5 mg QDtitrate to response75 mg QD
Social anxiety disorderadults12.5 mg QDtitrate to response37.5 mg QD
Premenstrual dysphoric disorderadults12.5 mg QD (continuous or luteal-phase)12.5 mg QD25 mg QD

Titration Increase in 12.5 mg/day increments at intervals of at least 1 week.

Renal Severe impairment: start 12.5 mg/day; max 50 mg/day (MDD, PD) or 37.5 mg/day (SAD).

Hepatic Severe impairment: start 12.5 mg/day; max 50 mg/day (MDD, PD) or 37.5 mg/day (SAD).

Instructions

Contraindications

Cautions

Adverse reactions

Pregnancy Associated with a less than 2-fold increase in cardiovascular malformations with first-trimester exposure; late exposure linked to postpartum hemorrhage and neonatal complications.

Lactation Undefined

⚠ BOXED WARNING

Classes and tags

Clinical profile

Direct muscarinic antagonism1 / 4

Mechanism of action: Paroxetine CR ballicule

Paroxetine CR ballicule: receptor binding, kinetics and half-life diagram

Open Paroxetine CR in the interactive console ↗

Memory aids: mascots and interaction avatars

Paroxetine CR PAXIL mascot mnemonic cartoon
“Pear rocks a teen (Paxil Rose)”
Crimson roses → antimuscarinic effects
Paroxetine CR CYP2D6 inhibitor avatar
CYP2D6 inhibitor (strong)

Open Paroxetine CR in the interactive console ↗